Skip to main content
Advertisement
Advertisement

BEAM

BEAM logo

Beam Therapeutics Inc. Common Stock

25.18
USD
Sponsored
-1.65
-6.17%
Sep 09, 15:59 UTC -4
Closed
exchange

After-Market

25.35

+0.18
+0.70%

BEAM Earnings Reports

Positive Surprise Ratio

BEAM beat 16 of 27 last estimates.

59%

Next Report

Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$12.33M
/
-$1.16
Implied change from Q2 26 (Revenue/ EPS)
+2416.42%
/
-1.69%
Implied change from Q3 25 (Revenue/ EPS)
+27.14%
/
+5.45%

Beam Therapeutics Inc. Common Stock earnings per share and revenue

On Aug 04, 2026, BEAM reported earnings of -1.18 USD per share (EPS) for Q2 26, missing the estimate of -1.12 USD, resulting in a -4.56% surprise. Revenue reached 490.00 thousand, compared to an expected 16.70 million, with a -97.07% difference. The market reacted with a +9.42% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -1.16 USD, with revenue projected to reach 12.33 million USD, implying an decrease of -1.69% EPS, and increase of 2416.42% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-
Surprise
-
FAQ
For Q2 2026, Beam Therapeutics Inc. Common Stock reported EPS of -$1.18, missing estimates by -4.56%, and revenue of $490.00K, -97.07% below expectations.
The stock price moved up 9.42%, changed from $25.91 before the earnings release to $28.35 the day after.
The next earning report is scheduled for Nov 02, 2026.
Based on 9 analysts, Beam Therapeutics Inc. Common Stock is expected to report EPS of -$1.16 and revenue of $12.33M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement